We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


EmendoBio Scientists Participate in National Neutropenia Network Patient Retreat

Scientists working in a lab.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Reinvigorated with purpose, Emendo Biotherapeutics (EmendoBio), returns to the lab after a heartfelt weekend meeting patients and their families at the National Neutropenia Network (NNN) Patient Retreat.

On July 14th, over 100 patients with the rare blood disorder came together from around the country to network, share resources, and learn more about current scientific developments in neutropenia. Held in Cincinnati, Ohio, EmendoBio’s top scientists were invited to attend the retreat as keynote speakers and given the opportunity to meet the very patients that are at the center of the Company’s research efforts.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Chief Operating Officer Asael Herman, Ph.D. ,and Executive Vice President of Research and Development, Rafi Emmanuel, Ph.D. presented findings from ongoing studies and answered patient questions about EmendoBio’s lead investigational product, EMD-101, which targets the most severe form of the condition, Severe Congenital Neutropenia (SCN).

“It’s a privilege to speak with families that have been searching for answers for so long,” explained Asael Herman, whose teams have been undertaking preclinical development of EMD-101 for 5 years. “Our allele-specific editing strategies allow our scientists to utilize our extremely specific and active gene editors to target the rarest of diseases, as well as more prevalent monogenic and even non-monogenic diseases, with the goal of opening the door to future therapeutics that were previously unimaginable. We have only just scratched the surface when it comes to realizing the full potential of gene editing, and EmendoBio is just getting started.” EMD-101 nearing clinical trials marks a significant milestone for the Company.

“Our annual retreat is meant to educate, raise awareness, and build community,” shared NNN’s executive director, Stephanie Long, whose youngest daughter has SCN. “Just as neutropenia patients fight for their lives, their loved ones are fighting for answers. Being able to share scientific updates made this year’s retreat extra special for so many of our members.” EmendoBio continues to actively advance its pipeline toward the clinic.